title: Effects of OsteoKing on osteoporotic rabbits.
abstract: Heng-Gu-Gu-Shang-Yu-He-Ji, also known as OsteoKing, is used as a herbal Traditional Chinese Medicine for the treatment of bone disease, including femoral head necrosis and osteoarthritis. However, whether OsteoKing has anti-osteoporotic properties has remained to be elucidated. The purpose of the present study was therefore to investigate the effects of OsteoKing on ovariectomy-induced osteoporosis in rabbits. Female New Zealand white rabbits were randomly divided into an ovariectomized (OVX) group and a sham-surgery group. The rabbits in the OVX group were subjected to an ovariectomy, while the rabbits in the sham group were subjected to the removal of an area of fat near the two ovaries. Bone mineral density, mechanical properties, serum biochemical parameters and micro-architecture were examined at 150 days post-OVX to characterize the experimental animal model. Once the osteoporotic rabbit model had been established, the rabbits in the OVX group were divided into the following groups: Model group, nilestriol group and 300 and 600 mg/kg OsteoKing groups, containing 16 rabbits in each group. OsteoKing and nilestriol were administered orally. The bone mineral density, mechanical properties, serum biochemical parameters, histology and micro-architecture were examined using dual-energy X-ray absorptiometric analysis, mechanical assessments, enzyme-linked immunosorbent assays, histopathological evaluation and micro-computerized tomography examination following 60 days and 120 days of treatment, respectively. Treatment with OsteoKing led to an elevation in the bone mineral density of the vertebra and serum phosphorus levels, reduced serum concentrations of osteocalcin, procollagen type I N-terminal peptide, tartrate-resistant acid phosphatase 5b and cross-linked N-telopeptide of type I collagen, improved mechanical properties (maximum load, stiffness and energy absorption capacity), and micro-architecture of the lumbar vertebra in the OVX osteoporotic rabbit model following treatment for 120 days. In conclusion, it was demonstrated that OsteoKing is effective in the prevention of estrogen deficiency-associated bone loss and may be a promising drug for the treatment of post-menopausal osteoporosis.
authors: School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan 650500, P.R. China.
authors: Lifen
authors: L
authors: Dai
authors: Trauma Center of Emergency Medicine Department, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.
authors: Haiying
authors: H
authors: Wu
authors: Research Center for Molecular Medicine, Kunming University, Kunming, Yunnan 650214, P.R. China.
authors: Shan
authors: S
authors: Yu
authors: Trauma Center of Emergency Medicine Department, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.
authors: Hongbin
authors: H
authors: Zhao
authors: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
authors: Lanjie
authors: L
authors: Xue
authors: Research Center for Molecular Medicine, Kunming University, Kunming, Yunnan 650214, P.R. China.
authors: Ming
authors: M
authors: Xu
authors: School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan 650500, P.R. China.
authors: Zhiqiang
authors: Z
authors: Shen
authors: Research Center for Molecular Medicine, Kunming University, Kunming, Yunnan 650214, P.R. China.
authors: Min
authors: M
authors: Hu
mesh_terms: D015502:Absorptiometry, Photon; D000135:Acid Phosphatase / Q000235:genetics / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004964:Estriol / Q000031:analogs & derivatives / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008159:Lumbar Vertebrae / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010024:Osteoporosis / Q000209:etiology / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D010052:Ovariectomy / Q000009:adverse effects; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D010758:Phosphorus / Q000378:metabolism; D011347:Procollagen / Q000235:genetics / Q000378:metabolism; D011800:Quinestrol / Q000031:analogs & derivatives; D011817:Rabbits; D000071681:Tartrate-Resistant Acid Phosphatase; D014055:Tomography, Emission-Computed
chemical_list: D050071:Bone Density Conservation Agents; D004365:Drugs, Chinese Herbal; D004967:Estrogens; D007527:Isoenzymes; D010446:Peptide Fragments; D011347:Procollagen; C510023:osteoking; C047202:procollagen Type I N-terminal peptide; D015675:Osteocalcin; D010758:Phosphorus; C010722:nylestriol; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D004964:Estriol; D011800:Quinestrol